Investigating the efficacy of baricitinib in new onset type 1 diabetes mellitus (bandit)—study protocol for a phase 2, randomized, placebo controlled trial

HIGHLIGHTS

• who: M. Waibel from the St Vincentu2019s Institute of Medical Research, Melbourne, Australia Institute, University of Adelaide and have published the Article: Investigating the efficacy of baricitinib in new onset type 1 diabetes mellitus (BANDIT)u2014study protocol for a phase 2, randomized, placebo controlled trial, in the Journal: (JOURNAL) of 26/02/2020
• what: The aim of this study is to determine if the JAK1/JAK2 inhibitor baricitinib impairs type 1 diabetes autoimmunity and preserves beta cell function. The aim is to assess whether baricitinib can reduce the loss of plasma C-peptide in patients . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.